AKT1 and acute lymphoblastic leukemia: Metformin, AMPK-dependently, blocked the activation of the UPR in acute lymphoblastic leukemia (ALL) cells and synergized with both AKT and the proviral insertion site in moloney murine leukemia virus (PIM-2) inhibitors [170].